Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, June 2, 2021
[ Wed, Jun 02nd 2021
] - WOPRAI
[ Wed, Jun 02nd 2021
] - WOPRAI
[ Wed, Jun 02nd 2021
] - WOPRAI
[ Wed, Jun 02nd 2021
] - WOPRAI
[ Wed, Jun 02nd 2021
] - WOPRAI
[ Wed, Jun 02nd 2021
] - WOPRAI
[ Wed, Jun 02nd 2021
] - WOPRAI
[ Wed, Jun 02nd 2021
] - WOPRAI
[ Wed, Jun 02nd 2021
] - WOPRAI
Tue, June 1, 2021
[ Tue, Jun 01st 2021
] - WOPRAI
[ Tue, Jun 01st 2021
] - WOPRAI
[ Tue, Jun 01st 2021
] - WOPRAI
[ Tue, Jun 01st 2021
] - WOPRAI
[ Tue, Jun 01st 2021
] - WOPRAI
[ Tue, Jun 01st 2021
] - WOPRAI
[ Tue, Jun 01st 2021
] - WOPRAI
[ Tue, Jun 01st 2021
] - WOPRAI
[ Tue, Jun 01st 2021
] - WOPRAI
[ Tue, Jun 01st 2021
] - WOPRAI
[ Tue, Jun 01st 2021
] - WOPRAI
[ Tue, Jun 01st 2021
] - WOPRAI
[ Tue, Jun 01st 2021
] - WOPRAI
[ Tue, Jun 01st 2021
] - WOPRAI
[ Tue, Jun 01st 2021
] - WOPRAI
[ Tue, Jun 01st 2021
] - WOPRAI
[ Tue, Jun 01st 2021
] - WOPRAI
[ Tue, Jun 01st 2021
] - WOPRAI
[ Tue, Jun 01st 2021
] - WOPRAI
Raghuram Selvaraju Maintained (BTAI) at Strong Buy with Increased Target to $176 on, Jun 1st, 2021
Raghuram Selvaraju of HC Wainwright & Co., Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Increased Target from $170 to $176 on, Jun 1st, 2021.
Raghuram has made no other calls on BTAI in the last 4 months.
There are 4 other peers that have a rating on BTAI. Out of the 4 peers that are also analyzing BTAI, 0 agree with Raghuram's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Raghuram
- Anita Dushyanth of "Berenberg" Initiated at Strong Buy and Held Target at $75 on, Friday, April 9th, 2021
- Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Decreased Target to $127 on, Thursday, April 1st, 2021
- Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $95 on, Thursday, April 1st, 2021
- Colin Bristow of "UBS" Initiated at Strong Buy and Held Target at $99 on, Monday, February 1st, 2021
